Unlocking Crohn's Disease: Amino Acid Metabolism in Fistula Patients

Wang, H. et al. Mesenchymal stem cells transplantation for perianal fistulas: a systematic review and meta-analysis of clinical trials. Stem Cell. Res. Ther. 14, 103 (2023). García-Olmo, D. et al. Prevalence of anal fistulas in europe: systematic literature reviews and population-based database analysis. Adv. Ther. 36, 3503–3518 (2019). Zanotti, C. et al. An assessment of the incidence of fistula-in-ano in four countries of the European union. Int. J. Colorectal Dis. 22, 1459–1462 (2007). Litta, F. et al. The pathogenesis of cryptoglandular anal fistula: new insight into the immunological profile. Colorectal Dis. 24, 1567–1575 (2022). Cao, S., Colonna, M. & Deepak, P. Pathogenesis of perianal fistulising crohn’s disease: current knowledge, gaps in understanding, and future research directions. J. Crohn’s Colitis. 17, 1010–1022 (2023). Wang, X. & Shen, B. Advances in perianal disease associated with crohn’s disease-Evolving approaches. Gastrointest. Endosc Clin. N Am. 29, 515–530 (2019). Rizzo, G. et al. Dysfunctional extracellular matrix remodeling supports perianal fistulizing crohn’s disease by a mechanoregulated activation of the epithelial-to-mesenchymal transition. Cell. Mol. Gastroenterol. Hepatol. 15, 741–764 (2023). Singh, J. P. et al. Navigating the complexities of perianal crohn’s disease: diagnostic strategies, treatment approaches, and future perspectives. World J. Gastroenterol. 30, 4745–4753 (2024). Munster, L. J. et al. Fistulizing perianal disease as a first manifestation of crohn’s disease: A systematic review and Meta-Analysis. J. Clin. Med. 13, 4734 (2024). Zabot, G. P. et al. Modern surgical strategies for perianal crohn’s disease. World J. Gastroenterol. 26, 6572–6581 (2020). Becker, M. A. J. et al. Clinical relevance of calprotectin in patients with perianal fistulas in crohn’s disease and cryptoglandular fistulas. United Eur. Gastroenterol. J. 13, 295–304 (2025). Li, J. et al. Magnetically guided capsule endoscopy and magnetic resonance enterography in children with crohn’s disease: manifestations and the value of assessing disease activity. Front. Pharmacol. 13, 894808 (2022). Zheng, X. et al. The role of amino acid metabolism in inflammatory bowel disease and other inflammatory diseases. Front. Immunol. 14, 1284133 (2023). Caio, G. et al. Nutritional treatment in crohn’s disease. Nutrients 13, 1628 (2021). Ling, Z. N. et al. Amino acid metabolism in health and disease. Signal. Transduct. Target. Ther. 8, 345 (2023). Bröer, S. Intestinal amino acid transport and metabolic health. Annu. Rev. Nutr. 43, 73–99 (2023). Li, B. et al. Nutritional strategies to reduce intestinal cell apoptosis by alleviating oxidative stress. Nutr. Rev. 83, e518–e532 (2025). Li, T. T. et al. Microbiota metabolism of intestinal amino acids impacts host nutrient homeostasis and physiology. Cell. Host Microbe. 32, 661–675 (2024). Liu, M. et al. The Tryptophan metabolite Indole-3-Carboxaldehyde alleviates mice with DSS-Induced ulcerative colitis by balancing amino acid Metabolism, inhibiting intestinal Inflammation, and improving intestinal barrier function. Molecules 28, 3704 (2023). Desmons, A. et al. High performance liquid chromatography-tandem mass spectrometry quantification of Tryptophan metabolites in human serum and stool-Application to clinical cohorts in inflammatory bowel diseases. J. Chromatogr. A. 1685, 463602 (2022). Adegbola, S. O. et al. Differences in amino acid and lipid metabolism distinguish crohn’s from idiopathic/cryptoglandular perianal fistulas by tissue metabonomic profiling and May offer clues to underlying pathogenesis. Eur. J. Gastroenterol. Hepatol. 33, 1469–1479 (2021). Geldof, J. et al. Classifying perianal fistulising crohn’s disease: an expert consensus to guide decision-making in daily practice and clinical trials. Lancet Gastroenterol. Hepatol. 7, 576–584 (2022). Danese, S. et al. Efficacy and safety of 48 weeks of Guselkumab for patients with crohn’s disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial. Lancet Gastroenterol. Hepatol. 9, 133–146 (2024). Vuyyuru, S. K. et al. Scoring indices for perianal fistulising crohn’s disease: A systematic review. J. Crohns Colitis. 18, 836–850 (2024). Zhang, Q. et al. A novel strategy for targeted lipidomics based on LC-Tandem-MS parameters Prediction, Quantification, and multiple statistical data mining: evaluation of lysophosphatidylcholines as potential cancer biomarkers. Anal. Chem. 91, 3389–3396 (2019). Hu, C. et al. Metabolic profiling of lysophosphatidylcholines in chlorpromazine hydrochloride- and N-acetyl-p-amino-phenoltriptolide-induced liver injured rats based on ultra-performance liquid chromatography quadrupole time-of-flight mass spectrometry. Hum. Exp. Toxicol. 41, 9603271221108320 (2022). FDA. Bioanalytical Method Validation Guidance for Industry FDA (United Stated, 2018). EMA. Guideline on bioanalytical method validation.: (EMEA/CHMP/EWP/192217/2009). European Medicines Agency EMA (Accessed February 2025). (2011). Triba, M. N. et al. PLS/OPLS models in metabolomics: the impact of permutation of dataset rows on the K-fold cross-validation quality parameters. Mol. Biosyst. 11, 13–19 (2015). Hu, C. et al. Metabolic profiling of 19 amino acids in triptolide-induced liver injured rats by gas chromatography-triple quadrupole mass spectrometry. Hum. Exp. Toxicol. 40, 1685–1697 (2021). Parian, A. M., Obi, M. & Fleshner, P. Management of perianal crohn’s disease. Am. J. Gastroenterol. 118, 1323–1331 (2023). Deng, X. et al. Disruption of branched-chain amino acid homeostasis promotes the progression of DKD via enhancing inflammation and fibrosis-associated epithelial-mesenchymal transition. Metabolism 162, 156037 (2025). Michaudel, C. et al. Rewiring the altered Tryptophan metabolism as a novel therapeutic strategy in inflammatory bowel diseases. Gut 72, 1296–1307 (2023). Nyström, N. et al. Mucosal and plasma metabolomes in New-onset paediatric inflammatory bowel disease: correlations with disease characteristics and plasma inflammation protein markers. J. Crohns Colitis. 17, 418–432 (2023). Yuan, Y. et al. Astragali radix vesicle-like nanoparticles improve energy metabolism disorders by repairing the intestinal mucosal barrier and regulating amino acid metabolism in sleep-deprived mice. J. Nanobiotechnol. 22, 768 (2024). Suarez, R. G. et al. Serum metabolites relate to mucosal and transmural inflammation in paediatric Crohn disease. J. Crohns Colitis. 18, 1832–1844 (2024). Li, S. et al. L-Arginine-Modified selenium nanozymes targeting M1 macrophages for oral treatment of ulcerative colitis. Small 21, e2408205 (2025). Reza, L. et al. European society of coloproctology: guidelines for diagnosis and treatment of cryptoglandular anal fistula. Colorectal Dis. 26, 145–196 (2024). Lapenna, D. Glutathione and glutathione-dependent enzymes: from biochemistry to gerontology and successful aging. Ageing Res. Rev. 92, 102066 (2023). Tratenšek, A. et al. Oxidative stress-related biomarkers as promising indicators of inflammatory bowel disease activity: A systematic review and meta-analysis. Redox Biol. 77, 103380 (2024). Dimou, A. et al. NMR-based metabolomic signature: an important tool for the diagnosis and study of pathogenesis of autoimmune hepatitis. Hepatology 80, 266–277 (2024). Hao, Y. et al. Microbial production of branched chain amino acids: advances and perspectives. Bioresour Technol. 397, 130502 (2024). Nemet, I. et al. Atlas of gut microbe-derived products from aromatic amino acids and risk of cardiovascular morbidity and mortality. Eur. Heart J. 44, 3085–3096 (2023). Jariyasopit, N. & Khoomrung, S. Mass spectrometry-based analysis of gut microbial metabolites of aromatic amino acids. Comput. Struct. Biotechnol. J. 21, 4777–4789 (2023). Gątarek, P. et al. Plasma Metabolic Disturbances in Parkinson’s Disease Patients. Biomedicines. 10, 3005 (2022). Vich Vila, A. et al. Untargeted faecal metabolomics for the discovery of biomarkers and treatment targets for inflammatory bowel diseases. Gut 73, 1909–1920 (2024). Harris, D. M. M. et al. Tryptophan degradation as a systems phenomenon in inflammation - an analysis across 13 chronic inflammatory diseases. EBioMedicine 102, 105056 (2024). Li, J. Y. et al. Arginine metabolism regulates the pathogenesis of inflammatory bowel disease. Nutr. Rev. 81, 578–586 (2023). Dragoni, G. et al. The impact of peptidyl arginine deiminase 4-Dependent neutrophil extracellular trap formation on the early development of intestinal fibrosis in crohn’s disease. J. Crohns Colitis. 19, jjae121 (2025). Yang, H. et al. A commensal protozoan attenuates clostridioides difficile pathogenesis in mice via arginine-ornithine metabolism and host intestinal immune response. Nat. Commun. 15, 2842 (2024).